has licensed three pneumococcal conjugate vaccines (PCV15, PCV20, and PCV21) and one pneumococcal polysaccharide vaccine (PPSV23) for protection against pneumococcal disease. A serotype is a ...

Prevenar 13 is a mixture of the outer sugar coating (polysaccharide ... child have ever had an allergic reaction to pneumococcal or diphtheria vaccines, or any of the ingredients listed at ...

NA: Not applicable; PCV-7: 7-valent pneumococcal conjugate vaccine; PCV-13: 13-valent pneumococcal conjugate vaccine; PPV23: 23-valent pneumococcal polysaccharide vaccine.

Participants were randomized to receive a single dose of either one of three lots of CAPVAXIVE or PPSV23 (pneumococcal 23-valent polysaccharide ... 13-valent conjugate vaccine], or cohort 3 ...

polysaccharide-based jab Pneumovax 23. Sanofi's new challenger is billed as a "next-generation" pneumococcal conjugate vaccine that, according to the company, is the first candidate with more than ...

No serious adverse events were considered to be related to the study vaccines. Post-dose 3, the VAX-24 Mid dose met target precedent Phase 2 non-inferiority (NI) criteria on relative ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

Merck & Co – known as MSD outside the US and Canada – has announced that its adult-specific 21-valent pneumococcal conjugate vaccine has been approved by the European Commission (EC). The vaccine, ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 ... followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses to Prevnar 20 in patients aged 18 ...

Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine ...

Noninferiority criteria were not met for some pneumococcal conjugate ... Quadrivalent polysaccharide–protein conjugate vaccines against serogroups A, C, W and Y are currently licensed worldwide.